Lapatinib nano-delivery systems: a promising future for breast cancer treatment

References

• GLOBOCAN. Cancer fact sheets 2012. [ cited 2017 Aug]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• WHO. Cancer fact sheet 2017. [ cited 2017 Aug]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
   Google Scholar
• GLOBOCAN. Breast cancer: estimated incidence, mortality and prevalence worldwide in 2012. [ cited 2017 Jul]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp
   Google Scholar
• Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786.
   PubMed Web of Science ®Google Scholar
• Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412–424.
   PubMedGoogle Scholar
• Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23–31.
   PubMed Web of Science ®Google Scholar
• Ellis IO, Cornelisse CJ, Schnitt SJ, et al. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs : tumors of the breast. World Health Organization Classification of Tumours. Lyon (France): IARCPress; 2003.
   Google Scholar
• Bennett NC, Farah CS. Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers. 2014;6(4):2296–2312.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14(24):8019–8026.
   PubMed Web of Science ®Google Scholar
• Malhotra GK, Zhao X, Band H, et al. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther. 2010;10(10):955–960.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
   PubMed Web of Science ®Google Scholar
• Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929–2943.
   PubMed Web of Science ®Google Scholar
• Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7(10):791–799.
   PubMed Web of Science ®Google Scholar
• Gusterson BA, Ross DT, Heath VJ, et al. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005;7(4):143–148.
   PubMed Web of Science ®Google Scholar
• Abdulkareem I, Zurmi I. Review of hormonal treatment of breast cancer. Niger J Clin Pract. 2012;15(1):9–14.
   PubMed Web of Science ®Google Scholar
• Kaliberov SA, Buchsbaum DJ. Cancer treatment with gene therapy and radiation therapy. Adv Cancer Res. 2012;115:221–263.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Mamounas EP, Hortobagyi GN, et al. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014;32(19):1979–1986.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Breast Cancer Treatment Cancer Society. [ cited 2017 Aug]. Available from: https://www.cancer.org/cancer/breast-cancer/treatment.html
   Google Scholar
• McDonald ES, Clark AS, Tchou J, et al. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57(Supplement1):9S–16S.
   PubMedGoogle Scholar
• Ligresti G, Libra M, Militello L, et al. Breast cancer: molecular basis and therapeutic strategies. Mol Med Rep. 2008;1(4):451–458.
   PubMed Web of Science ®Google Scholar
• Marmé F, Schneeweiss A. Personalized therapy in breast cancer. Oncol Res Treat. 2012;35(Suppl. 1):28–33.
   Google Scholar
• Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121(10):3797–3803.
   PubMed Web of Science ®Google Scholar
• Munagala R, Aqil F, Gupta RC. Promising molecular targeted therapies in breast cancer. Indian J Pharmacol. 2011;43(3):236–245.
   PubMed Web of Science ®Google Scholar
• Wieduwilt M, Moasser M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566–1584.
   PubMed Web of Science ®Google Scholar
• Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv. 2012;2012:1–17.
   Google Scholar
• Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist. 2008;13(10):1114–1119.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. FDA Approval for Lapatinib Ditosylate Cancer Institute. [ cited 2017 Aug]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-lapatinib
   Google Scholar
• Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717–733.
   PubMed Web of Science ®Google Scholar
• Gao H, Wang Y, Chen C, et al. Incorporation of lapatinib into core–shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm. 2014;461(1):478–488.
   PubMedGoogle Scholar
• Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol. 2007;25(23):3397–3398.
   PubMed Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426–1447.
   PubMed Web of Science ®Google Scholar
• Burris III HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23(23):5305–5313.
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Guchelaar H-J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692–706.
   PubMed Web of Science ®Google Scholar
• Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor—2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31:2332–2348.
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Mead M. Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstet Gynecol. 2016;28(1):59–69.
   PubMed Web of Science ®Google Scholar
• Burris HA, Taylor CW, Jones SF, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res. 2009;15(21):6702–6708.
   PubMed Web of Science ®Google Scholar
• Dai C, Ma S, Wang F, et al. Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. Oncotarget. 2015;6(19):17738–17752.
   PubMed Web of Science ®Google Scholar
• Castellino S, O’Mara MJ, Koch KM, et al. Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab Dispos. 2012;40:139–150.
   PubMed Web of Science ®Google Scholar
• Dai C-L, Tiwari AK, Wu C-P, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008;68(19):7905–7914.
   PubMed Web of Science ®Google Scholar
• Wang H, Li F, Du C, et al. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. Mol Pharm. 2014;11(8):2600–2611.
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15(24):7519–7527.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res. 2016;103:26–48.
   PubMed Web of Science ®Google Scholar
• Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004;11(1):35–43.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs. 2008;17(6):865–878.
   PubMed Web of Science ®Google Scholar
• Vannini I, Zoli W, Fabbri F, et al. Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines. Anticancer Drugs. 2009;20(10):918–925.
   PubMed Web of Science ®Google Scholar
• Collins D, Crown J, O’Donovan N, et al. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Invest New Drugs. 2010;28(4):433–444.
   PubMed Web of Science ®Google Scholar
• Li F, Danquah M, Singh S, et al. Paclitaxel-and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Deliv Transl Res. 2011;1(6):420–428.
   PubMed Web of Science ®Google Scholar
• Vergara D, Bellomo C, Zhang X, et al. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine. 2012;8(6):891–899.
   PubMed Web of Science ®Google Scholar
• Wei Y, Xu S, Wang F, et al. A novel combined micellar system of lapatinib and paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor‐2 positive breast tumor in vitro. J Pharm Sci. 2015;104(1):165–177.
   PubMed Web of Science ®Google Scholar
• Dehghan Kelishady P, Saadat E, Ravar F, et al. Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation. Pharm Dev Technol. 2015;20(8):1009–1017.
   PubMed Web of Science ®Google Scholar
• Hu H, Lin Z, He B, et al. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. J Control Release. 2015;220:189–200.
   PubMed Web of Science ®Google Scholar
• Ravar F, Saadat E, Kelishadi PD, et al. Liposomal formulation for co-delivery of paclitaxel and lapatinib, preparation, characterization and optimization. J Liposome Res. 2016;26(3):175–187.
   PubMed Web of Science ®Google Scholar
• Wang Y-L, Overstreet A-M, Chen M-S, et al. Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR. Oncotarget. 2015;6(13):11150.
   PubMedGoogle Scholar
• Fang J, Sawa T, Maeda H Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. In: Maeda H, Kabanov A, Kataoka K, Okano T, editors. Polymer drugs in the clinical stage. Advances in Experimental Medicine and Biology, vol 519. Boston (MA):Springer; 2004. p. 29–49.
   Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine. 2013;8(9):1509–1528.
   PubMed Web of Science ®Google Scholar
• Huo ZJ, Wang SJ, Wang ZQ, et al. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: therapeutic efficacy evaluation. Cancer Sci. 2015;106(10):1429–1437.
   PubMed Web of Science ®Google Scholar
• Li S-D, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta. 2009;1788(10):2259–2266.
   PubMed Web of Science ®Google Scholar
• Bazak R, Houri M, El Achy S, et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141(5):769–784.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975–999.
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Cao S, et al. Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles. Nanotechnology. 2012;23(43):435101.
   PubMed Web of Science ®Google Scholar
• Wan X, Zheng X, Pang X, et al. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Int J Pharm. 2015;484(1–2):16–28.
   PubMedGoogle Scholar
• Wan X, Zheng X, Pang X, et al. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer. Colloids Surf B Biointerfaces. 2015;136:817–827.
   PubMed Web of Science ®Google Scholar
• Fu Q, Sun J, Zhang W, et al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov. 2009;4(3):262–272.
   PubMed Web of Science ®Google Scholar
• Wang J, Mongayt D, Torchilin VP. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly (ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target. 2005;13(1):73–80.
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1–18.
   PubMed Web of Science ®Google Scholar
• Mobasseri R, Karimi M, Tian L, et al. Hydrophobic lapatinib encapsulated dextran-chitosan nanoparticles using a toxic solvent free method: fabrication, release property & in vitro anti-cancer activity. Mater Sci Eng C. 2017;74:413–421.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang S, Ruan S-B, et al. Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism. Acta Pharmacol Sin. 2014;35(6):846–852.
   PubMed Web of Science ®Google Scholar
• Bantchev G, Lu Z, Lvov Y. Layer-by-layer nanoshell assembly on colloids through simplified washless process. J Nanosci Nanotechnol. 2009;9(1):396–403.
   PubMed Web of Science ®Google Scholar
• Arvizo RR, Miranda OR, Moyano DF, et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PloS One. 2011;6(9):e24374.
   PubMed Web of Science ®Google Scholar
• Koutras AK, Evans TJ. The epidermal growth factor receptor family in breast cancer. Onco Targets Ther. 2008;1:5–19.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996;13(6):1359–1365.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630–1639.
   PubMed Web of Science ®Google Scholar
• Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, et al. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology. 2010;79(1–2):129–135.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26(34):5544–5552.
   PubMed Web of Science ®Google Scholar
• Guan Y, Huang J, Zuo L, et al. Effect of pluronic P123 and F127 block copolymer on P-glycoprotein transport and CYP3A metabolism. Arch Pharm Res. 2011;34(10):1719–1728.
   PubMed Web of Science ®Google Scholar
• Alakhova DY, Kabanov AV. Pluronics and MDR reversal: an update. Mol Pharm. 2014;11(8):2566–2578.
   PubMed Web of Science ®Google Scholar
• Schmolka IR. Artificial skin I. Preparation and properties of pluronic F‐127 gels for treatment of burns. J Biomed Mater Res A. 1972;6(6):571–582.
   Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci. 1988;85(18):6949–6953.
   PubMed Web of Science ®Google Scholar
• Zhang S, Jingjing L, Cheng Y. Metronomic chemotherapy-a new path to treat advanced non-small cell lung cancer. Chin J Lung Cancer. 2015;18(4):232–239.
   Google Scholar
• Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7(8):455–465.
   PubMed Web of Science ®Google Scholar
• Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5(3):186–192.
   PubMedGoogle Scholar
• Celia C, Ferrati S, Bansal S, et al. Sustained zero‐order release of intact ultra‐stable drug‐loaded liposomes from an implantable nanochannel delivery system. Adv Healthc Mater. 2014;3(2):230–238.
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951.
   PubMed Web of Science ®Google Scholar
• English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013;17(2):85–99.
   PubMed Web of Science ®Google Scholar
• Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34(1):157–164.
   PubMed Web of Science ®Google Scholar
• Gniazdowska E, Koźmiński P, Bańkowski K, et al. Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer. Eur J Med Chem. 2014;87:493–499.
   PubMed Web of Science ®Google Scholar
• Bird BRH, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14(1):14–24.
   PubMed Web of Science ®Google Scholar
• Wang B, Zhu C, Liu L, et al. Synthesis of a new conjugated polymer for cell membrane imaging by using an intracellular targeting strategy. Polym Chem. 2013;4(20):5212–5215.
   Web of Science ®Google Scholar
• Bunz UH. Poly (aryleneethynylene) s: syntheses, properties, structures, and applications. Chem Rev. 2000;100(4):1605–1644.
   PubMed Web of Science ®Google Scholar